GSK scrapes up 2% sales growth despite politics, generics

Europe is once again a big drag on pharma earnings. For GlaxoSmithKline ($GSK), the European ball and chain slowed drug and vaccine sales 6%. Good thing U.S. revenues took a 9% leap--and emerging…
Read the full story: News